RxDoctor Payments Data

Nestor Ivkov, MD

Neurology · Chicago, ILNPI 1023028750

Payments from drug & device makers

$14,828in general payments, 2019–2025

Across 376 payments — averaging $39.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Novartis$1K
  • EMD Serono, Inc.$779
  • Biogen$752
  • Supernus Pharmaceuticals, Inc.$680
  • Bristol Myers Squibb$612
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$5,18035%
  • Travel & lodging$6634%
  • Food & beverage$8,98661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,828 in reported general payments places this provider in the 75th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$91,886
Medicare patients
450
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate46$403,039
Avonex Pen (4 Pack)Interferon Beta-1a16$132,311
AustedoDeutetrabenazine14$102,551
CopaxoneGlatiramer Acetate17$95,322
Nurtec OdtRimegepant Sulfate14$25,410
Dalfampridine ErDalfampridine47$22,819
FingolimodFingolimod Hcl16$14,083
VimpatLacosamide13$13,761
Lacosamide48$12,914
RytaryCarbidopa/Levodopa11$5,831
Levetiracetam164$5,505
Carbamazepine ErCarbamazepine25$5,141
Pyridostigmine Bromide25$2,304
Entacapone17$2,148
Dimethyl Fumarate11$2,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$752$403,03946 claims
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$222$197,87331 claims
PfizerNurtec Odt$38$25,41014 claims
UCB, Inc.Vimpat$174$13,76113 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$33$8,13536 claims
Lilly USA, LLCOlanzapine$24$86948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 790 neurology providers in Illinois.

Other neurology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →